Title:
BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFβ
Document Type and Number:
WIPO Patent Application WO/2021/115456
Kind Code:
A1
Abstract:
Provided is a polypeptide, comprising, from N-terminus to C-terminus, a) at least a variable region of a heavy chain of a heavy-chain antibody (VHH domain) that binds protein Programmed Death Ligand 1 (PD-L1), operably linked to IgG Fc binding domain; and b) human TGFβRII, or a fragment thereof capable of binding TGFβ. An antibody comprises the said polypeptide, the amino acid sequences of the said antibody, cloning or expression vectors, cells and methods for expressing or isolating the antibodies are further provided. Therapeutic compositions comprising the said antibodies, and the methods for treating cancers and other diseases with the bispecific antibodies are also provided.
Inventors:
CHEN YUNYING (CN)
LI JING (CN)
LI JING (CN)
Application Number:
PCT/CN2020/135928
Publication Date:
June 17, 2021
Filing Date:
December 11, 2020
Export Citation:
Assignee:
WUXI BIOLOGICS SHANGHAI CO LTD (CN)
WUXI BIOLOGICS IRELAND LTD (IE)
WUXI BIOLOGICS IRELAND LTD (IE)
International Classes:
C07K19/00; A61K38/17; A61P35/00; C07K14/495; C07K14/71
Domestic Patent References:
| WO2018205985A1 | 2018-11-15 | |||
| WO2018218215A1 | 2018-11-29 | |||
| WO2019222252A1 | 2019-11-21 |
Foreign References:
| CN110198738A | 2019-09-03 | |||
| CN109641963A | 2019-04-16 | |||
| CN106103488A | 2016-11-09 | |||
| US20180002436A1 | 2018-01-04 |
Other References:
See also references of EP 4073124A4
Attorney, Agent or Firm:
ANJIE LAW FIRM (CN)
Download PDF: